SAN DIEGO, Aug. 28, 2018 /PRNewswire-PRWeb/ -- Achieve TMS, the nation's largest and most experienced provider of deep
"While TMS is approved by the FDA for treatment of depression, and most insurances cover this treatment, it was also approved last week for the treatment of OCD and is being studied for treatment of other conditions such as autism spectrum disorder and PTSD. Dr. Oberman has over a decade of experience leading clinical studies that demonstrate how TMS impacts and ultimately helps normalize neural circuitry for patients suffering from these devastating conditions," said Shashita Inamdar, M.D., Ph.D. and medical director and founder of Achieve TMS. "As part of her role with Achieve TMS, Dr. Oberman will be hosting symposia, webinars and training workshops for medical practitioners interested in learning more about the science behind TMS treatments."
"I am excited to be able to participate in ground-breaking therapeutic studies and interventions that help us understand neural circuitry dysfunction and brain plasticity," said Dr. Oberman. "It is a rare opportunity for a scientist such as myself to be able to share the data and information we are uncovering with the broader medical community."
Dr. Oberman earned a Bachelor of Science degree from Emory University, double majoring in Neuroscience and Psychology. She then went on to earn an M.A. and PhD in Experimental Psychology from the University of California, San Diego developing EEG biomarkers to characterize circuit dysfunction in children with autism spectrum disorder. She then completed an NIH-funded postdoctoral fellowship at Beth Israel Deaconess Medical Center, Harvard Medical School where she pioneered the use of TMS in autism spectrum disorder. She was promoted to Instructor at Harvard Medical School and remained there for 6 years. She then directed the Neuroplasticity and Autism Spectrum Disorder Program at Bradley Hospital, Brown University Medical School before relocating to the Washington D.C. area to serve as the Clinical Program Leader for the Center for Neuroscience and Regenerative Medicine, with appointments both at the Uniformed Services University of Health Science and the National Institutes of Health where she is leading a series of multi-site TMS trials for both autism and traumatic brain injury. She has published over 50 peer-reviewed articles and gained international attention for her work.
For the treatment of depression, Deep TMS (dTMS) works by administering magnetic pulses through an H-coil on the scalp that is targeted to the mood center of the brain. The magnetic fields induce electrical currents that stimulate under-active neurons, helping to reset brain chemistry, resulting in improved sleep, concentration and overall mood. It is safe, non-invasive and highly effective for those who are treatment resistant and/or have experienced little or no relief from medication. As of August 17, 2018, dTMS has also been approved by the FDA for treatment of obsessive compulsive order (OCD).
In more than 60 clinical studies globally on dTMS for treatment of depression, statistically significant response and remission rates have been recorded. The therapy is well tolerated by patients, causing no adverse effects. Treatment sessions are prescribed five days per week for six weeks, with each session lasting 20 minutes. There is no sedation involved, no significant side effects and no down time.
For more information please contact Achieve TMS at 866-575-7219 or visit http://www.achievetms.com.
SOURCE Achieve TMS
Subscribe to our Free Newsletters!